Outlook Therapeutics (OTLK) announced that Russell Trenary has stepped down as the company’s president and CEO, effective immediately. Lawrence ...

Mr. Kenyon has served as the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as ...

Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a report issued ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

On Wednesday, Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $1.7 which represents a decrease of $-3.19 or -65.24% from the prior close of $4.89. The stock opened at $0.98 and ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

(RTTNews) - Shares of Outlook Therapeutics Inc. (OTLK), a biopharmaceutical company specializing in ophthalmic treatments, are down over 70% in premarket trading, following mixed results from its ...

Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients. In the NORSE EIGHT trial ...

Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) increased during the last reporting period, rising from 2.99M to 3.23M. This put 20.09% of the company's publicly available shares short.